< Back to situations

[ORGANIZATION]

Nivolumab

Featured in 3 tracked stories · first seen

Situations

[ACTIVE] [HEALTH] [US]

Replimune melanoma therapy FDA approval

3 clusters · 18 sources · last updated

Latest: FDA approves new oncolytic viral therapy for anti‑PD‑1‑refractory melanoma

Following the FDA’s Cellular, Tissue and Gene Therapies Advisory Committee vote of 10‑3 in late July 2026, the agency granted accelerated approval on 6 August 2026 to Replimune’s oncolytic herpes‑virus therapy RP1, marke

[ACTIVE] [HEALTH] [BR]

Brazil cancer drug access crisis

2 clusters · 3 sources · last updated

Latest: Brazilian Cancer Patients Face Drug Shortage and Funding Crisis

In late July 2026, reports highlighted extreme financial barriers for Brazilian children with serious cancers, including a 10‑year‑old needing a R$3 million bone‑marrow transplant drug and a 7‑year‑old receiving palliati